CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (NASDAQ: CERO) is a clinical-stage biopharmaceutical company advancing chimeric engulfment receptor T-cell (CER-T) therapies for hematologic malignancies and solid tumors. The company reached public markets through a de-SPAC business combination with Phoenix Biotech Acquisition Corp, a blank-check vehicle sponsored by Phoenix Biotech Sponsor LLC that completed its initial public offering in 2021. The merger closed in early 2024, bringing CERO's proprietary cell-therapy platform to a Nasdaq listing. The company filed its most recent Form 10-Q with the SEC on August 14, 2026. For comprehensive filings, financials, and analytics on CERO and the broader SPAC universe, sign up for full data access at SpacDesk.